Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center

Rhea-AI Summary

Pulsenmore (NASDAQ: PLSM) announced its first U.S. commercial engagement on Feb 2, 2026, following FDA clearance for its home pregnancy ultrasound product. The company signed a services agreement with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles to provide Pulsenmore ES home ultrasound services.

The agreement enables remote prenatal monitoring for patients at a center that manages approximately 1,500 pregnancies per year, with the goal of reducing unnecessary diagnostic visits and expanding telehealth-driven prenatal care.

Positive

• Received FDA clearance for its home pregnancy ultrasound product
• Signed first U.S. commercial services agreement with CFFM
• Partner center manages approximately 1,500 pregnancies per year, enabling immediate clinical use

Negative

• Initial commercialization limited to a single medical center, constraining near-term scale
• Press release discloses no commercial terms or revenue guidance from the agreement

News Market Reaction

+4.79%

1 alert

+4.79% News Effect

+2.4% Peak Tracked

+$2M Valuation Impact

$40M Market Cap

0.3x Rel. Volume

On the day this news was published, PLSM gained 4.79%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.4% during that session. This price movement added approximately $2M to the company's valuation, bringing the market cap to $40M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Agreement value: $4.5 million Pilot duration: 18 months Binding order units: 25,000 units +5 more

8 metrics

Agreement value $4.5 million Potential value over five years in Clalit agreement (regulatory_context)

Pilot duration 18 months Pilot period before five‑year Clalit term (regulatory_context)

Binding order units 25,000 units Separate binding order for Pulsenmore ES (historical news summary)

Annual minimum units 2,000 units Minimum yearly Pulsenmore FC purchases in Clalit deal

Annual return cap 1,000 units Maximum units Clalit may return per year

Pregnancies managed 1,500 per year CFFM annual pregnancy volume in Los Angeles

Share price $5.85 Pre-news price on publication date

Market cap $39,342,206 Pre-news equity value for PLSM

Market Reality Check

Price: $5.75 Vol: Volume 5,696 is only 0.22...

low vol

$5.75 Last Close

Volume Volume 5,696 is only 0.22x the 20-day average (26,451), suggesting a subdued pre-news trading backdrop. low

Technical Shares at $5.85 are below the $6.23 200-day MA and sit 43.09% under the 52-week high of $10.28, though only 5.05% above the 52-week low of $5.5687.

Historical Context

1 past event · Latest: Jan 26 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Jan 26	Commercial agreement	Positive	+3.9%	Strategic Clalit deal for Pulsenmore FC with multi‑year commercial potential.

Pattern Detected

The last commercial/strategic agreement headline drew a positive price reaction, aligning with the constructive nature of that news.

Recent Company History

Over the past weeks, Pulsenmore advanced commercialization of its home ultrasound platforms. On Jan 26, 2026, it signed a strategic agreement with Clalit Health Services for the Pulsenmore FC at-home follicular monitoring service, potentially worth $4.5 million over five years after an 18‑month pilot, and the stock rose about 3.89%. Today’s U.S. commercial engagement similarly extends its remote ultrasound footprint from Israel into the American prenatal market.

Market Pulse Summary

This announcement highlights Pulsenmore’s first U.S. commercial engagement, extending its FDA‑author...

Analysis

This announcement highlights Pulsenmore’s first U.S. commercial engagement, extending its FDA‑authorized home prenatal ultrasound into a Los Angeles high‑risk pregnancy center managing about 1,500 pregnancies annually. It follows the Clalit agreement, potentially worth $4.5 million over five years after an 18‑month pilot. Investors may track adoption rates at CFFM, future U.S. partnerships, and how revenues from existing commitments such as the 25,000-unit order and Clalit ramp translate into reported results.

Key Terms

fda approval, telehealth, telemedicine, maternal-fetal medicine, +1 more

5 terms

fda approval regulatory

"following receipt of FDA approval for its home pregnancy ultrasound product."

FDA approval is the U.S. Food and Drug Administration’s formal authorization for a drug, vaccine, or medical device to be marketed and sold after reviewers determine it meets standards for safety and effectiveness. For investors it’s a pivotal milestone because it opens the door to legal, large-scale sales and can sharply boost revenue potential while reducing regulatory uncertainty—like receiving a safety certificate that lets a new bridge carry traffic and tolls.

telehealth technical

"home ultrasound and telehealth technology, addressing one of the fastest-growing needs"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

telemedicine technical

"Positioned at the intersection of digital health, telemedicine, and femtech"

Telemedicine is the delivery of healthcare services remotely through digital communication tools, such as video calls or online messaging. It allows patients to consult with doctors and medical professionals without visiting a clinic in person. For investors, telemedicine represents a growing sector that combines technology and healthcare, potentially transforming how medical care is accessed and delivered worldwide.

maternal-fetal medicine medical

"includes multidisciplinary experts in maternal-fetal medicine."

A medical specialty that manages high-risk pregnancies and the health of both the pregnant person and the developing baby, providing advanced diagnostics, treatments and procedures to prevent or address complications. Investors watch this field because demand for related drugs, diagnostic tests, medical devices and specialist services rises with demographic trends, clinical breakthroughs and regulatory or reimbursement changes — like a specialized crew steering a ship through stormy waters to protect valuable cargo.

obstetric medical

"and specializes in obstetric care for high-risk pregnancies."

Obstetric describes medical care and services related to pregnancy, labor and delivery, and the immediate postpartum period. Investors watch obstetric activity because it drives demand for hospitals, clinics, medical devices, pharmaceuticals and staffing, and it can be sensitive to regulation, birth-rate trends and reimbursement—think of it as the part of healthcare that handles childbirth, which affects revenues and costs for companies serving that market.

AI-generated analysis. Not financial advice.

OMER, Israel, Feb. 2, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the United States, following receipt of FDA approval for its home pregnancy ultrasound product.

At the end of January 2026, the Company (through its subsidiary) entered into a services agreement with the Center for Fetal Medicine & Women's Ultrasound, a fetal medicine and women's ultrasound center located in LA California (the "CFFM").

Under the agreement, CFFM will purchase Pulsenmore ES home ultrasound services, enabling patients to benefit from remote monitoring while reducing unnecessary visits to the diagnostic center.

Pulsenmore redefines prenatal care through clinically validated home ultrasound and telehealth technology, addressing one of the fastest-growing needs in global healthcare: high-quality care delivered beyond the clinic. Positioned at the intersection of digital health, telemedicine, and femtech, Pulsenmore enables remote prenatal monitoring that improves access and continuity of care and enhances patient experience.

CFFM is a prenatal diagnostic center in California that provides a wide range of specialized services and includes multidisciplinary experts in maternal-fetal medicine. The center manages approximately 1,500 pregnancies per year, operates from two locations in the Los Angeles area and specializes in obstetric care for high-risk pregnancies.

"Pulsenmore's ultrasound system marks a new era in maternal-fetal care, empowering expectant mothers with safe, guided access to ultrasound imaging from home or work, while keeping clinicians closely connected throughout the entire process." said Dr. Lawrence Platt, head of CFFM.

Dr. Elazar Sonnenschein, CEO of Pulsenmore, commented: "We are pleased to announce today Pulsenmore's first commercial agreement in the United States, marking another significant step forward following our recent FDA clearance. The agreement with CFFM, a highly professional and leading medical center specializing in the management of high-risk pregnancies, represents an important milestone in the implementation of our strategic plan in the U.S. market, where we see substantial clinical and business potential.

This agreement will enable the deployment of a remote pregnancy monitoring model that places the patient and her needs at the center of care. This collaboration allows us to begin operating in a gradual and responsible manner in a market where many women face limited access to obstetric healthcare services, and to demonstrate how home-based ultrasound can become an integral part of routine medical care."

About Pulsenmore

Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com

This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected outcome of Pulsenmore's engagement with CFFM. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

Photo - https://mma.prnewswire.com/media/2874665/Compostion_Ultrasound.jpg

Investor Contact:

Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsenmore-announces-first-commercial-engagement-with-a-leading-us-based-medical-center-302676244.html

SOURCE Pulsenmore Ltd.

FAQ

What did Pulsenmore (PLSM) announce on February 2, 2026 regarding U.S. commercialization?

Pulsenmore announced its first U.S. commercial engagement with a Los Angeles fetal medicine center. According to Pulsenmore, the agreement enables deployment of Pulsenmore ES home ultrasound services for remote prenatal monitoring at CFFM.

How does the Pulsenmore FDA clearance affect PLSM's U.S. market entry?

FDA clearance permitted Pulsenmore to begin commercial operations in the United States. According to Pulsenmore, the clearance enabled the services agreement with CFFM and supports gradual, responsible market rollout.

What services will Pulsenmore provide to the Center for Fetal Medicine & Women's Ultrasound (CFFM)?

Pulsenmore will provide its ES home ultrasound services for remote pregnancy monitoring to CFFM patients. According to Pulsenmore, the service aims to reduce unnecessary diagnostic visits while keeping clinicians connected.

How large is the patient base at CFFM that will use Pulsenmore services (PLSM)?

CFFM manages about 1,500 pregnancies per year, forming the initial patient base for the Pulsenmore deployment. According to Pulsenmore, CFFM operates from two Los Angeles locations and specializes in high-risk obstetric care.

Will the Pulsenmore agreement materially change PLSM revenue immediately?

The announcement does not disclose financial terms or expected revenue from the agreement. According to Pulsenmore, the engagement is an initial commercial deployment intended to demonstrate clinical and operational integration.

What is the strategic significance of the CFFM deal for Pulsenmore (PLSM)?

The CFFM agreement represents Pulsenmore's first U.S. commercial customer and a proof point for its remote prenatal model. According to Pulsenmore, it advances the company’s U.S. strategic plan and clinical adoption pathway.